AbbVie’s Contract With Express Scripts Puts Gilead On Defense…And Industry On Notice
Express Scripts decision to provide AbbVie’s new Viekira Pak as the exclusive treatment option for genotype 1 hepatitis C patients under its national preferred formulary leaves Gilead’s Sovaldi and Harvoni out in the cold and spotlights growing pricing pressure as payers are willing to deny coverage for market-leading drugs.
You may also be interested in...
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.
Data from a high-profile Phase III COVID-19 vaccine trial will be released the first week of February, management said.
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.